


Curriculum Vitae

	Name (First Name, Middle Name Last Name)	Laurent Peyrin-Biroulet
	Position	MD, PhD
	Affiliation	Nancy University Hospital
	Country	France
	Major Field	Inflammatory Bowel Disease

Education Background			
Institution and Location	Degree	Year	Field of Study
University of Lorraine, Vandoeuvre-les-Nancy, France	MS	2001	Molecular Biology
University of Lorraine, Vandoeuvre-les-Nancy, France	MD	2005	Gastroenterology
University of Lorraine, Inserm U1256, Vandoeuvre-les-Nancy, France	PhD	2008	Molecular Biology
University of Lorraine, Inserm U1256, Vandoeuvre-les-Nancy, France	Prof. of Medicine	2009	Gastroenterology

Professional Experience			
Dates	Title	Mentor	Institution and Location
Since 2019	Head of Inserm Team 2	-	University of Lorraine, Inserm U1256, Vandoeuvre-les-Nancy, France
Since 2009	Professor of medicine	Prof. MA Bigard	Department of Gastroenterology, Nancy University Hospital, Nancy, France
2008-2009	Research fellow	Prof. WJ Sandborn	Mayo clinic, Rochester, Minnesota, USA
2006-2007	Research fellow	Prof. JF Colombel	Inserm Unit 995, Lille University, Lille, France
2005-2006	Assistant Professor of Medicine	Prof. MA Bigard	Department of Gastroenterology, Nancy University Hospital, Nancy, France

Professional Organizations		
Dates	Title	Institution
Since 2020	President	European Crohn's and Colitis Organisation (ECCO)
Since 2020	Scientific secretary	International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)
Since 2015	President	<i>Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)</i>

Scientific Publication

Over the last decade, Laurent Peyrin-Biroulet has published more than 850 articles referenced in PubMed.

The 10 best original research publications of the past 10 years:

1. **Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.** Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. *Lancet Gastroenterol Hepatol.* 2022 Apr;7(4):294-306. PMID: 35120656.
2. **Long-Term Overconsumption of Fat and Sugar Causes a Partially Reversible Pre-inflammatory Bowel Disease State.** Arnone D, Vallier M, Hergalant S, Chabot C, Ndiaye NC, Moulin D, Aignatoaei AM, Alberto JM, Louis H, Boulard O, Mayeur C, Dreumont N, Peuker K, Strigli A, Zeissig S, Hansmannel F, Chamaillard M, Kökten T, Peyrin-Biroulet L. *Front Nutr.* 2021 Nov 18;8:758518. PMID: 34869528.
3. **Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.** Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempinski R, Filip R, Hospodarsky I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. *Lancet.* 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3. PMID: 34090625.
4. **Development of an index to define overall disease severity in IBD.** Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Geary R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. *Gut.* 2018; 67:244-254. PMID: 27780886.
5. **Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort.** Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L; International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group; International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. *Gut.* 2017 Apr;66(4):588-596. PMID: 26646934.
6. **Development and validation of the Nancy histological index for UC.** Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L. *Gut.* 2017; 66:43-49. PMID: 26464414.
7. **Methyl-deficient diet promotes colitis and SIRT1-mediated endoplasmic reticulum stress.** Melhem H, Hansmannel F, Bressenot A, Battaglia-Hsu SF, Billioud V, Alberto JM, Gueant JL, Peyrin-Biroulet L. *Gut.* 2016; 65:595-606. PMID: 25608526.
8. **Comparing histological activity indexes in UC.** Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L. *Gut.* 2015 Sep;64(9):1412-8. PMID: 25246423.
9. **Clinical disease activity, C-reactive protein normalization and mucosal healing in Crohn's disease in the SONIC trial.** Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. *Gut.* 2014; 63:88-95. PMID: 23974954.

10. **Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease.** Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, Rousseaux C, Dubuquoy C, Decourcelle C, Saudemont A, Tachon M, Béclin E, Odou MF, Neut C, Colombel JF, Desreumaux P. Gut. 2012 Jan;61(1):78-85. PMID: 21940721.

Honors & Awards

- Since 2019: “Highly Cited Researchers” worldwide
- Since 2019: Top-rated expert in Crohn’s Disease in the world according to “Expertscape”
- 2019: Visiting professorship in inflammatory bowel disease from the University of Chicago Medicine, USA
- 2017: International award and visiting professorship in inflammatory bowel disease from Division of Gastroenterology Icahn School of Medicine at Mount Sinai, USA
- 2008: Rising star award from the United European Gastroenterology Federation (UEGF)